Download App

Log in to access Online Inquiry
Company Overview More
Sansheng Pharmaceutical is an investment holding company mainly engaged in the development, production, marketing and sales of pharmaceutical products. The company's main products include recombinant human thrombopoietin products, tumor necrosis factor-α inhibitors and recombinant human erythropoietin. The products are sold under the brands of Tebio, Yisep, iBio, and Cyber. The company sells products in the domestic market and overseas markets such as Sri Lanka, the Dominican Republic and Thailand. The company's subsidiaries include Jisi Co., Ltd., Hong Kong Sansheng Medical Co., Ltd. And Shenyang Sansheng Pharmaceutical Co., Ltd. The company is also engaged in project management and consulting through its subsidiaries.
CEO: Jing Lou
Market: Hong Kong motherboard
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

01530 3SBIO
5.710+0.090+1.60%
YOY
Do not show
Hide blank lines
(FY)2021/12/31(Q6)2021/06/30(FY)2020/12/31(Q6)2020/06/30
Assets
Current assets
Inventory
11.46% 690.52M 19.59% 681.5M 17.23% 619.51M 26.71% 569.88M
Accounts receivable
40.27% 1.38B 3.53% 1.22B -3.47% 982.97M -23.61% 1.18B
Advance deposits and other receivables
30.75% 768.73M 15.41% 582.66M 24.46% 587.92M -33.25% 504.85M
Cash and equivalents
-7.21% 2.87B -23.03% 2.92B 48.39% 3.09B 174.88% 3.79B
Secured deposit
46.71% 184.59M 403.8% 111.86M 470.03% 125.82M 47.99% 22.2M
Financial assets at fair value-current assets
49.27% 1.9B 135.44% 1.88B 169.58% 1.27B -15.87% 799.32M
Total current assets
16.63% 7.79B 7.71% 7.4B 45.34% 6.68B 34.77% 6.87B
Non-current assets
Property, plant and equipment
31.24% 3.44B 44.95% 3.04B 31.81% 2.62B 15.35% 2.1B
Advance payment
-8.23% 298.84M -- -- -- 325.63M -- --
Long-term receivables
-- -- -- -- -66.44% 2.2M -59.95% 3.58M
Associated company interest
-7.06% 696.82M 29.06% 748.61M 26.34% 749.72M 51.26% 580.05M
Interests in Joint Venture
-45.76% 3.77M -25.51% 5.67M -7.03% 6.95M 33.73% 7.61M
Financial assets at fair value-non-current assets
-30.86% 620.68M -- -- -- 897.72M -- --
Other investments
-- -- -- -- -- -- 45.26% 929.66M
Intangible assets
-2.6% 1.85B -12.62% 1.85B -12.32% 1.9B -5.25% 2.12B
Goodwill
-1.91% 3.84B -7.42% 3.89B -5.47% 3.92B 2.52% 4.2B
Deferred tax assets
27.91% 280.48M 49.8% 228.49M 69.95% 219.28M 18.37% 152.53M
Special items of non-current assets
8.39% 388.04M 114.18% 1.38B -28.38% 358.01M 33.19% 642.82M
Total non-current assets
3.85% 11.42B 3.8% 11.14B 7.69% 11B 9.51% 10.73B
Total assets
8.68% 19.21B 5.33% 18.54B 19.37% 17.68B 18.15% 17.6B
Liabilities
Current liabilities
Accounts payable
13.34% 230.41M 29.33% 214.95M 35.74% 203.29M -2.62% 166.2M
Tax payable
27.93% 73.71M -17.37% 84.09M 170.06% 57.62M 49.65% 101.77M
Other payables and accrued expenses
17.09% 921.21M -4.15% 842.35M -13.92% 786.75M -4.28% 878.81M
Bank loans and overdrafts
-58.3% 150.19M -67.36% 150.13M -25.58% 360.15M -60.68% 460M
Financial lease liabilities-current liabilities
50.76% 10.56M 24.6% 9.29M 28.17% 7.01M -- 7.46M
Deferred income-current liabilities
-6.11% 33.91M -7.99% 34.16M -2.97% 36.11M 1.55% 37.12M
Total current liabilities
-2.13% 1.42B -19.16% 1.33B -9.98% 1.45B -30.12% 1.65B
Net current assets
21.83% 6.37B 16.21% 6.07B 75.21% 5.23B 90.83% 5.22B
Total assets less current liabilities
9.65% 17.79B 7.86% 17.21B 22.96% 16.23B 27.25% 15.95B
Non-current liabilities
Long-term bank loan
207.88% 164.15M 377.51% 64.63M 301.29% 53.32M -90.37% 13.53M
Financial lease liabilities-non-current liabilities
0.5% 32.38M 23.94% 33.6M 712.79% 32.22M 407.11% 27.11M
Deferred tax liability
-2.86% 264.47M -2.96% 266.19M 1.55% 272.24M 2.25% 274.33M
Deferred income-non-current liabilities
28.58% 396.63M 38.68% 319.4M 27.3% 308.46M -12.77% 230.31M
Convertible notes and bonds
-7.71% 2.27B -38.88% 2.39B 6.8% 2.46B 70.03% 3.91B
Other non-current liabilities
-11.28% 5.57M 4.47% 6.05M 6.97% 6.28M -5.85% 5.79M
Total non-current liabilities
0.03% 3.13B -30.96% 3.08B 10.42% 3.13B 49.49% 4.46B
Total liabilities
-0.66% 4.55B -27.77% 4.41B 3.03% 4.58B 14.29% 6.11B
Total assets less total liabilities
11.95% 14.66B 22.92% 14.13B 26.39% 13.09B 20.31% 11.49B
Total equity and non-current liabilities
9.65% 17.79B 7.86% 17.21B 22.96% 16.23B 27.25% 15.95B
Equity
Share capital
0% 155K 0.65% 156K 0% 155K 0% 155K
Share premium
-3.39% 4.15B 1.03% 4.34B -0.23% 4.3B -0.23% 4.3B
Other reserves
26.35% 8.08B 15.86% 7.39B 20.2% 6.39B 38.31% 6.38B
Shareholders' Equity
14.39% 12.23B 9.89% 11.73B 11.06% 10.69B 19.7% 10.68B
Non-controlling interest
1.1% 2.43B 193.09% 2.4B 227.4% 2.4B 28.95% 817.54M
Total equity
11.95% 14.66B 22.92% 14.13B 26.39% 13.09B 20.31% 11.49B
Total equity and total liabilities
8.68% 19.21B 5.33% 18.54B 19.37% 17.68B 18.15% 17.6B
Currency Unit
CNYCNYCNYCNY
Accounting Standards
IASIASIASIAS
Audit Opinions
Unqualified Opinion--Unqualified Opinion--
Auditor
Ernst & Young accounting firm--Ernst & Young accounting firm--

Q6, Q9, and FY are cumulative quarterly reports: Q6 is the interim report; Q9 is third quarter report; FY is the annual report.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%